Chardan Capital Maintains Neutral on Avidity Biosciences, Maintains $72 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Neutral and maintains $72 price target.
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Neutral and maintains $72 price target.